10:30

i love angio....made me some mad money today

Upgraded by Sun Trust Rbsn Humphrey from Neutral to Buy

Rating: BUY
Target: $29
Sector: Healthcare

We have selected AngioDynamics as the top pick in our MedTech universe for 2007. In our judgment, there are several catalysts converging that will ignite share price appreciation in the New Year. Specifically, the pending RITA acquisition affords the company opportunities, both in the U.S. and Europe, to fuel annual sales growth beyond our original 25% projection. RITA
broadens AngioDynamics’ product assortment and leverages its formidable sales force, provides access to larger market opportunities with differentiated products, and AngioDynamics gains access to additional R&D with expertise in tumor ablation and port technology. In addition, we cite the ramp of Sotradecol sales in the U.S. largely driven by the sole distributorship arrangement, introduction of new products with higher margins, resolution of the Diomed case and entrance into new markets, including oncology.